Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

49.760
+0.9201.88%
Volume:16.90M
Turnover:828.82M
Market Cap:206.26B
PE:36.75
High:49.960
Open:48.860
Low:48.180
Close:48.840
52wk High:54.450
52wk Low:28.480
Shares:4.15B
HK Float Shares:4.15B
Volume Ratio:0.63
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.354
ROE:11.38%
ROA:7.60%
PB:3.68
PE(LYR):36.75
PS:7.48

Loading ...

Wuxi Biologics (cayman) Stock Advances 3.5% in Hong Kong

Dow Jones
·
Jul 20

HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%

Tiger Newspress
·
Jul 20

Movement Alert|WuXi Biologics Rises 3.24% in Regular Trading, Star Fund Manager Zhao Feng Adds Stock as New Top-10 Holding

Market Focus
·
Jul 20

Wuxi Biologics (cayman) Stock Slips 6.0% in Hong Kong

Dow Jones
·
Jul 17

Movement Alert|WuXi Biologics Falls 3.26% in Regular Trading, Trading at 37.54 HKD

Market Focus
·
Jul 17

Wuxi XDC Files HKEX Next-day Disclosure Return, Share Capital Rises by 1,121,205 Shares

Reuters
·
Jul 17

Research Monkey Prices Soar to A$20k, Supply Falls Short as CRO Industry Orders Rebound

Stock News
·
Jul 16

Wuxi Biologics (cayman) Stock Rallies 3.5% in Hong Kong

Dow Jones
·
Jul 15

Movement Alert|WuXi Biologics Rises 3.66% in Regular Trading, Life Sciences Sector Rallies as FDA Approval Momentum Persists

Market Focus
·
Jul 15

Wuxi XDC Files HKEX Next-day Disclosure Return, Share Capital Rises by 2,004,133 Shares

Reuters
·
Jul 14

Movement Alert|WuXi Biologics Declines 3.27% in Regular Trading, Trading at HK$37.0

Market Focus
·
Jul 14

Wuxi Biologics (cayman) Stock Falls 1.7% in Hong Kong

Dow Jones
·
Jul 13

WuXi Biologics (Cayman) (SEHK:2269) Wins FDA Inspection As Its Undervalued Case Builds

Simply Wall St.
·
Jul 12

TOT Biopharm Schedules Board Meeting to Review Interim Results

Reuters
·
Jul 10

Wuxi XDC Schedules Board Meeting to Review Interim Results

Reuters
·
Jul 10

Wuxi Biologics (cayman) Stock Rises 2.4% in Hong Kong

Dow Jones
·
Jul 10

Movement Alert|WuXi Biologics Rises 3.45% in Regular Trading, MFG8 Drug Substance Facility FDA Approval Continues to Boost Sentiment

Market Focus
·
Jul 10

Wuxi Biologics (cayman) Stock Rallies 3.9% in Hong Kong

Dow Jones
·
Jul 09

Wuxi Biologics' MFG8 Drug Substance Facility Secures FDA Pli Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

THOMSON REUTERS
·
Jul 09

WUXI BIO Shares Surge Over 6% as MFG8 Facility Passes Key FDA Pre-Approval Inspection

Deep News
·
Jul 09